Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Buy” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) gained 5.28 Percent and closed its previous trading session at $14.95. The stock traded with the average Volume of 737.11 Million at the end of last session.
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has the Market Capitalization of 664.23 Million. The Stock has its 52-week High of $17.24 and 52-Week Low of $ 9.30 and it touched its 52-week high on 12/19/16 and 52-Week Low on 04/18/17.
The company reported its last earnings Actual EPS of $0.27/share. While, the analyst predicted that the company could provide an EPS of $0.25/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.02/share which shows an Earnings Surprise of 8 Percent.
Several analysts are forecasting growth estimate of Sucampo Pharmaceuticals, Inc. for the current quarter to be -51.5%. Their projections for the Next Quarter growth is 34.8 percent. While for the Next 5 years, the company could expect a growth of 3% per annum, whereas in the past Five years Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) showed a growth of 46.47 Percent per annum.
Sell side analysts plays vital role in buying and selling a stock where 2 analysts rated Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 34.14% where SMA50 and SMA200 are 39.19% and 38.9% respectively.
The company shows its Return on Assets (ROA) value of -33.5%. The Return on Equity (ROE) value stands at -148.2%. While it’s Return on Investment (ROI) value is 9.6%.
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) currently has a Weekly Volatility of 9.05% percent while its Monthly Volatility is at 5.03% percent. While talking about Performance of the Stock, Sucampo Pharmaceuticals, Inc. currently has a Weekly performance of 23.55%, monthly performance percentage is 39.72 percent, Quarterly performance is 21.54 percent, 6 months performance shows a percent value of 48.02% and Yearly Performance is -5.38 percent.
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.